{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T18:08:46Z","timestamp":1772906926804,"version":"3.50.1"},"reference-count":130,"publisher":"Walter de Gruyter GmbH","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cell based chemosensitivity and resistance testing is an attractive approach that offers functional measurement of drug response\n                    <jats:italic>ex vivo<\/jats:italic>\n                    with the ultimate goal to guide the choice of chemotherapy for various cancers. Thus, it has a great potential to select patients for the optimal treatment option, thereby offering a tool for personalized cancer therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    Despite several decades of intensive scientific efforts\n                    <jats:italic>ex-vivo<\/jats:italic>\n                    tests are still not incorporated in the standard of care. Limited access to fresh tumor tissue, unsatisfactory models and single readout as endpoint constitute major hindrance. Thus, establishing and validating clinically useful and reliable model systems still remains a major challenge.\n                  <\/jats:p>\n                  <jats:p>\n                    Here we present malignant effusions as valuable sources for\n                    <jats:italic>ex-vivo<\/jats:italic>\n                    chemosensitivity and resistance testing. Accumulation of a malignant effusion in the pleura, peritoneum or pericardium is often the first diagnostic material for both primary malignant mesothelioma and a broad spectrum of metastatic adenocarcinoma originating from lung-, breast-, ovary- and gastro-intestinal organs as well as lymphoma.\n                  <\/jats:p>\n                  <jats:p>\n                    In contrast to biopsies, in these effusions malignant cells are easily accessible and often abundant. Effusion derived cells can occur dissociated or forming three-dimensional papillary structures that authentically recapitulate the biology of the corresponding tumor tissue and offer models for\n                    <jats:italic>ex vivo<\/jats:italic>\n                    testing. In addition, effusions have the advantage of being available prior to or concurrent with the pathological review, thus constituting an excellent source of viable cells for simultaneous molecular profiling, biomarker analysis and for establishing primary cells for studying tumor biology and resistance mechanisms.\n                  <\/jats:p>\n                  <jats:p>For a reliable test, however, a careful validation is needed, taking into account the inherited heterogeneity of malignant tumors, but also the complex interplay between malignant and benign cells, which are always present in this setting.<\/jats:p>","DOI":"10.1515\/pp-2016-0013","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T09:18:19Z","timestamp":1473931099000},"page":"119-133","source":"Crossref","is-referenced-by-count":2,"title":["Chemosensitivity and resistance testing in malignant effusions with focus on primary malignant mesothelioma and metastatic adenocarcinoma"],"prefix":"10.1515","volume":"1","author":[{"given":"Adam","family":"Szulkin","sequence":"first","affiliation":[{"name":"Division of Pathology, Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T\u00fcnde","family":"Szatm\u00e1ri","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Hjerpe","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Dobra","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Laboratory Medicine , Karolinska Institutet , Stockholm , Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,9,15]]},"reference":[{"key":"2025120909192062275_j_pp-2016-0013_ref_001_w2aab3b7b2b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"1. Heldin P, Pertoft H. Synthesis and assembly of the hyaluronan-containing coats around normal human mesothelial cells. Exp Cell Res 1993;208:422\u20139.","DOI":"10.1006\/excr.1993.1264"},{"key":"2025120909192062275_j_pp-2016-0013_ref_002_w2aab3b7b2b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"2. Cotran RS, Karnovsky MJ. Ultrastructural studies on the permeability of the mesothelium to horseradish peroxidase. J Cell Biol 1968;37:123\u201337.","DOI":"10.1083\/jcb.37.1.123"},{"key":"2025120909192062275_j_pp-2016-0013_ref_003_w2aab3b7b2b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"3. Fedorko ME, Hirsch JG, Fried B. Studies on transport of macromolecules and small particles across mesothelial cells of the mouse omentum. II. Kinetic features and metabolic requirements. Exp Cell Res 1971;69:313\u201323.","DOI":"10.1016\/0014-4827(71)90230-8"},{"key":"2025120909192062275_j_pp-2016-0013_ref_004_w2aab3b7b2b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"4. Sahn SA. The pathophysiology of pleural effusions. Annu Rev Med 1990;41:7\u201313.","DOI":"10.1146\/annurev.me.41.020190.000255"},{"key":"2025120909192062275_j_pp-2016-0013_ref_005_w2aab3b7b2b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"5. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004;2004:CD002916.","DOI":"10.1002\/14651858.CD002916.pub2"},{"key":"2025120909192062275_j_pp-2016-0013_ref_006_w2aab3b7b2b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"6. Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, et\u2009al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 2013;45:44\u20138.","DOI":"10.1097\/PAT.0b013e32835bc848"},{"key":"2025120909192062275_j_pp-2016-0013_ref_007_w2aab3b7b2b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"7. Dejmek A, Hjerpe A. The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79\u2006% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 2005;32:160\u20136.","DOI":"10.1002\/dc.20202"},{"key":"2025120909192062275_j_pp-2016-0013_ref_008_w2aab3b7b2b1b6b1ab2b1b8Aa","unstructured":"8. Michael CW, Chhieng D, Bedrossian CWM, editors. Cytohistology of the serous membranes. New York: Cambridge University Press, 2015."},{"key":"2025120909192062275_j_pp-2016-0013_ref_009_w2aab3b7b2b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"9. Hjerpe A, Ascoli V, Bedrossian CW, Boon ME, Creaney J, Davidson B, et\u2009al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta cytologica 2015;59:2\u201316.","DOI":"10.4103\/1742-6413.170726"},{"key":"2025120909192062275_j_pp-2016-0013_ref_010_w2aab3b7b2b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"10. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et\u2009al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788\u201395.","DOI":"10.1067\/mtc.2001.116560"},{"key":"2025120909192062275_j_pp-2016-0013_ref_011_w2aab3b7b2b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"11. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et\u2009al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18:1196\u2013202.","DOI":"10.1093\/annonc\/mdm093"},{"key":"2025120909192062275_j_pp-2016-0013_ref_012_w2aab3b7b2b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"12. Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et\u2009al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362\u20139.","DOI":"10.1183\/09031936.00039510"},{"key":"2025120909192062275_j_pp-2016-0013_ref_013_w2aab3b7b2b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"13. Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin\/pemetrexed and radiotherapy. Lung Cancer 2011;71:75\u201381.","DOI":"10.1016\/j.lungcan.2009.08.019"},{"key":"2025120909192062275_j_pp-2016-0013_ref_014_w2aab3b7b2b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"14. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et\u2009al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007\u201313.","DOI":"10.1200\/JCO.2008.20.3943"},{"key":"2025120909192062275_j_pp-2016-0013_ref_015_w2aab3b7b2b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"15. Elkiran ET, Kaplan MA, Sevinc A, Aksoy S, Demirci U, Seker M, et\u2009al. Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. Med Oncol 2012;29:3147\u201354.","DOI":"10.1007\/s12032-012-0276-y"},{"key":"2025120909192062275_j_pp-2016-0013_ref_016_w2aab3b7b2b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"16. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, et\u2009al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111\u201321.","DOI":"10.1016\/S0169-5002(02)00180-0"},{"key":"2025120909192062275_j_pp-2016-0013_ref_017_w2aab3b7b2b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"17. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et\u2009al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636\u201344.","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2025120909192062275_j_pp-2016-0013_ref_018_w2aab3b7b2b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"18. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, et\u2009al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923\u20137.","DOI":"10.1093\/annonc\/mdi187"},{"key":"2025120909192062275_j_pp-2016-0013_ref_019_w2aab3b7b2b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"19. Buikhuisen WA, Hiddinga BI, Baas P, van Meerbeeck JP. Second line therapy in malignant pleural mesothelioma: A systematic review. Lung Cancer 2015;89:223\u201331.","DOI":"10.1016\/j.lungcan.2015.06.018"},{"key":"2025120909192062275_j_pp-2016-0013_ref_020_w2aab3b7b2b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"20. Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, Grossi F. Advances in treatment of mesothelioma. Expert Opin Pharmacother 2016;17:1197\u2013205.","DOI":"10.1080\/14656566.2016.1176145"},{"key":"2025120909192062275_j_pp-2016-0013_ref_021_w2aab3b7b2b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"21. Fennell DA, Gaudino G, O\u2018Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136\u201347.","DOI":"10.1038\/ncponc1039"},{"key":"2025120909192062275_j_pp-2016-0013_ref_022_w2aab3b7b2b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"22. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1:591\u2013601.","DOI":"10.1016\/S1556-0864(15)30366-X"},{"key":"2025120909192062275_j_pp-2016-0013_ref_023_w2aab3b7b2b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"23. Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, et\u2009al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24:1443\u20138.","DOI":"10.1200\/JCO.2005.04.3190"},{"key":"2025120909192062275_j_pp-2016-0013_ref_024_w2aab3b7b2b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"24. Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, et\u2009al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer 2010;11:30\u20135.","DOI":"10.3816\/CLC.2010.n.005"},{"key":"2025120909192062275_j_pp-2016-0013_ref_025_w2aab3b7b2b1b6b1ab2b1c25Aa","doi-asserted-by":"crossref","unstructured":"25. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et\u2009al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25\u201330.","DOI":"10.1200\/JCO.1999.17.1.25"},{"key":"2025120909192062275_j_pp-2016-0013_ref_026_w2aab3b7b2b1b6b1ab2b1c26Aa","doi-asserted-by":"crossref","unstructured":"26. Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, et\u2009al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60:259\u201363.","DOI":"10.1016\/j.lungcan.2007.09.018"},{"key":"2025120909192062275_j_pp-2016-0013_ref_027_w2aab3b7b2b1b6b1ab2b1c27Aa","doi-asserted-by":"crossref","unstructured":"27. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008;99:44\u201350.","DOI":"10.1038\/sj.bjc.6604421"},{"key":"2025120909192062275_j_pp-2016-0013_ref_028_w2aab3b7b2b1b6b1ab2b1c28Aa","doi-asserted-by":"crossref","unstructured":"28. Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, et\u2009al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer 2003;4:294\u20137.","DOI":"10.3816\/CLC.2003.n.009"},{"key":"2025120909192062275_j_pp-2016-0013_ref_029_w2aab3b7b2b1b6b1ab2b1c29Aa","doi-asserted-by":"crossref","unstructured":"29. Hillerdal G, Sorensen JB, Sundstrom S, Riska H, Vikstrom A, Hjerpe A. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008;3:1325\u201331.","DOI":"10.1097\/JTO.0b013e31818b174d"},{"key":"2025120909192062275_j_pp-2016-0013_ref_030_w2aab3b7b2b1b6b1ab2b1c30Aa","doi-asserted-by":"crossref","unstructured":"30. Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev 1985;12:51\u20137.","DOI":"10.1016\/0305-7372(85)90018-0"},{"key":"2025120909192062275_j_pp-2016-0013_ref_031_w2aab3b7b2b1b6b1ab2b1c31Aa","doi-asserted-by":"crossref","unstructured":"31. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et\u2009al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542\u201350.","DOI":"10.1056\/NEJMoa061884"},{"key":"2025120909192062275_j_pp-2016-0013_ref_032_w2aab3b7b2b1b6b1ab2b1c32Aa","doi-asserted-by":"crossref","unstructured":"32. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et\u2009al. A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320\u20139.","DOI":"10.1093\/jnci\/djg036"},{"key":"2025120909192062275_j_pp-2016-0013_ref_033_w2aab3b7b2b1b6b1ab2b1c33Aa","doi-asserted-by":"crossref","unstructured":"33. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 2004;11:559\u201395.","DOI":"10.3892\/or.11.3.559"},{"key":"2025120909192062275_j_pp-2016-0013_ref_034_w2aab3b7b2b1b6b1ab2b1c34Aa","doi-asserted-by":"crossref","unstructured":"34. Bunn Jr PA. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 2002;20:23S\u201333S.","DOI":"10.1200\/JCO.2002.20.17.3565"},{"key":"2025120909192062275_j_pp-2016-0013_ref_035_w2aab3b7b2b1b6b1ab2b1c35Aa","doi-asserted-by":"crossref","unstructured":"35. Pillai RN, Ramalingam SS. Advances in the diagnosis and treatment of non-small cell lung cancer. Mol Cancer Ther 2014;13:557\u201364.","DOI":"10.1158\/1535-7163.MCT-13-0669"},{"key":"2025120909192062275_j_pp-2016-0013_ref_036_w2aab3b7b2b1b6b1ab2b1c36Aa","doi-asserted-by":"crossref","unstructured":"36. Rothschild SI. Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers 2015;7:930\u201349.","DOI":"10.3390\/cancers7020816"},{"key":"2025120909192062275_j_pp-2016-0013_ref_037_w2aab3b7b2b1b6b1ab2b1c37Aa","doi-asserted-by":"crossref","unstructured":"37. Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism 2015;64:S16\u201321.","DOI":"10.1016\/j.metabol.2014.10.027"},{"key":"2025120909192062275_j_pp-2016-0013_ref_038_w2aab3b7b2b1b6b1ab2b1c38Aa","doi-asserted-by":"crossref","unstructured":"38. Ross MB, Buzdar AU, Smith TL, Eckles N, Hortobagyi GN, Blumenschein GR, et\u2009al. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer 1985;55:341\u20136.","DOI":"10.1002\/1097-0142(19850115)55:2<341::AID-CNCR2820550206>3.0.CO;2-7"},{"key":"2025120909192062275_j_pp-2016-0013_ref_039_w2aab3b7b2b1b6b1ab2b1c39Aa","doi-asserted-by":"crossref","unstructured":"39. Johnston SR. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer 2011;47:S38\u201347.","DOI":"10.1016\/S0959-8049(11)70145-9"},{"key":"2025120909192062275_j_pp-2016-0013_ref_040_w2aab3b7b2b1b6b1ab2b1c40Aa","doi-asserted-by":"crossref","unstructured":"40. Gonzalez-Martin A, Sanchez-Lorenzo L, Bratos R, Marquez R, Chiva L. First-line and maintenance therapy for ovarian cancer: current status and future directions. Drugs 2014;74:879\u201389.","DOI":"10.1007\/s40265-014-0221-9"},{"key":"2025120909192062275_j_pp-2016-0013_ref_041_w2aab3b7b2b1b6b1ab2b1c41Aa","doi-asserted-by":"crossref","unstructured":"41. Petrillo M, Nero C, Amadio G, Gallo D, Fagotti A, Scambia G. Targeting the hallmarks of ovarian cancer: The big picture. Gynecol Oncol 2016;142:176\u201383.","DOI":"10.1016\/j.ygyno.2016.03.037"},{"key":"2025120909192062275_j_pp-2016-0013_ref_042_w2aab3b7b2b1b6b1ab2b1c42Aa","doi-asserted-by":"crossref","unstructured":"42. Korkmaz T, Seber S, Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials. Crit Rev Oncol Hematol 2016;98:180\u20138.","DOI":"10.1016\/j.critrevonc.2015.10.006"},{"key":"2025120909192062275_j_pp-2016-0013_ref_043_w2aab3b7b2b1b6b1ab2b1c43Aa","doi-asserted-by":"crossref","unstructured":"43. Marchetti C, Palaia I, De Felice F, Musella A, Donfracesco C, Vertechy L, et\u2009al. Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients. Cancer Treat Rev 2016;42:41\u20136.","DOI":"10.1016\/j.ctrv.2015.10.011"},{"key":"2025120909192062275_j_pp-2016-0013_ref_044_w2aab3b7b2b1b6b1ab2b1c44Aa","doi-asserted-by":"crossref","unstructured":"44. Schunselaar LM, Quispel-Janssen JM, Neefjes JJ, Baas P. A catalogue of treatment and technologies for malignant pleural mesothelioma. Expert Rev Anticancer Ther 2016;16:455\u201363.","DOI":"10.1586\/14737140.2016.1162100"},{"key":"2025120909192062275_j_pp-2016-0013_ref_045_w2aab3b7b2b1b6b1ab2b1c45Aa","doi-asserted-by":"crossref","unstructured":"45. Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev 2015;41:27\u201334.","DOI":"10.1016\/j.ctrv.2014.10.007"},{"key":"2025120909192062275_j_pp-2016-0013_ref_046_w2aab3b7b2b1b6b1ab2b1c46Aa","doi-asserted-by":"crossref","unstructured":"46. Shea M, Costa DB, Rangachari D. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. Ther Adv Respir Dis 2016;10:113\u201329.","DOI":"10.1177\/1753465815617871"},{"key":"2025120909192062275_j_pp-2016-0013_ref_047_w2aab3b7b2b1b6b1ab2b1c47Aa","doi-asserted-by":"crossref","unstructured":"47. Zeichner SB, Terawaki H, Gogineni K:A. Review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer Basic Clin Res 2016;10:25\u201336.","DOI":"10.4137\/BCBCR.S32783"},{"key":"2025120909192062275_j_pp-2016-0013_ref_048_w2aab3b7b2b1b6b1ab2b1c48Aa","doi-asserted-by":"crossref","unstructured":"48. Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol 2015;38:422\u201330.","DOI":"10.1097\/COC.0000000000000059"},{"key":"2025120909192062275_j_pp-2016-0013_ref_049_w2aab3b7b2b1b6b1ab2b1c49Aa","doi-asserted-by":"crossref","unstructured":"49. Schramm A, De Gregorio N, Widschwendter P, Fink V, Huober J. Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review. Breast care 2015;10:173\u20138.","DOI":"10.1159\/000431029"},{"key":"2025120909192062275_j_pp-2016-0013_ref_050_w2aab3b7b2b1b6b1ab2b1c50Aa","doi-asserted-by":"crossref","unstructured":"50. Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev 2016;25:71\u20136.","DOI":"10.1183\/16000617.0071-2015"},{"key":"2025120909192062275_j_pp-2016-0013_ref_051_w2aab3b7b2b1b6b1ab2b1c51Aa","doi-asserted-by":"crossref","unstructured":"51. Christoph DC, Eberhardt WE. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Current Opin Oncol 2014;26:171\u201381.","DOI":"10.1097\/CCO.0000000000000053"},{"key":"2025120909192062275_j_pp-2016-0013_ref_052_w2aab3b7b2b1b6b1ab2b1c52Aa","doi-asserted-by":"crossref","unstructured":"52. Papa S, Popat S, Shah R, Prevost AT, Lal R, McLennan B, et\u2009al. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy. J Thorac Oncol 2013;8:783\u20137.","DOI":"10.1097\/JTO.0b013e31828c2b26"},{"key":"2025120909192062275_j_pp-2016-0013_ref_053_w2aab3b7b2b1b6b1ab2b1c53Aa","doi-asserted-by":"crossref","unstructured":"53. Sweeney CJ, Sandler AB. Treatment of advanced (stages III and IV) non-small-cell lung cancer. Current Prob Cancer 1998;22:85\u2013132.","DOI":"10.1016\/S0147-0272(98)90010-1"},{"key":"2025120909192062275_j_pp-2016-0013_ref_054_w2aab3b7b2b1b6b1ab2b1c54Aa","doi-asserted-by":"crossref","unstructured":"54. Blayney JK, Ceresoli GL, Castagneto B, O\u2018Brien ME, Hasan B, Sylvester R, et\u2009al. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. Eur J Cancer 2012;48:2983\u201392.","DOI":"10.1016\/j.ejca.2012.05.018"},{"key":"2025120909192062275_j_pp-2016-0013_ref_055_w2aab3b7b2b1b6b1ab2b1c55Aa","doi-asserted-by":"crossref","unstructured":"55. Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2012;70:743\u201354.","DOI":"10.1007\/s00280-012-1965-0"},{"key":"2025120909192062275_j_pp-2016-0013_ref_056_w2aab3b7b2b1b6b1ab2b1c56Aa","doi-asserted-by":"crossref","unstructured":"56. Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, et\u2009al. ERCC1, MLH1, MSH2, MSH6, and betaIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer 2013;14:558\u201367, e553.","DOI":"10.1016\/j.cllc.2013.04.013"},{"key":"2025120909192062275_j_pp-2016-0013_ref_057_w2aab3b7b2b1b6b1ab2b1c57Aa","unstructured":"57. Abakay A, Abakay O, Tanrikulu AC, Sezgi C, Sen H, Kaya H, et\u2009al. Effects of treatment regimens on survival in patients with malignant pleural mesothelioma. Eur Rev Med Pharmacol Sci 2013;17:19\u201324."},{"key":"2025120909192062275_j_pp-2016-0013_ref_058_w2aab3b7b2b1b6b1ab2b1c58Aa","doi-asserted-by":"crossref","unstructured":"58. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591\u2013603.","DOI":"10.1056\/NEJMra050152"},{"key":"2025120909192062275_j_pp-2016-0013_ref_059_w2aab3b7b2b1b6b1ab2b1c59Aa","unstructured":"59. Srour EF, Brandt JE, Briddell RA, Leemhuis T, van Besien K, Hoffman R. Human CD34+ HLA-DR- bone marrow cells contain progenitor cells capable of self-renewal, multilineage differentiation, and long-term in vitro hematopoiesis. Blood Cells 1991;17:287\u201395."},{"key":"2025120909192062275_j_pp-2016-0013_ref_060_w2aab3b7b2b1b6b1ab2b1c60Aa","unstructured":"60. Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep 1985;69:615\u201332."},{"key":"2025120909192062275_j_pp-2016-0013_ref_061_w2aab3b7b2b1b6b1ab2b1c61Aa","doi-asserted-by":"crossref","unstructured":"61. Samson DJ, Seidenfeld J, Ziegler K, Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004;22:3618\u201330.","DOI":"10.1200\/JCO.2004.04.077"},{"key":"2025120909192062275_j_pp-2016-0013_ref_062_w2aab3b7b2b1b6b1ab2b1c62Aa","doi-asserted-by":"crossref","unstructured":"62. Morgan MM, Johnson BP, Livingston MK, Schuler LA, Alarid ET, Sung KE, et\u2009al. Personalized in vitro cancer models to predict therapeutic response: challenges and a framework for improvement. Pharmacol Ther 2016. pii: S0163-7258(16)30078-X. doi: 10.1016\/j.pharmthera.2016.05.007. [Epub ahead of print] Review.","DOI":"10.1016\/j.pharmthera.2016.05.007"},{"key":"2025120909192062275_j_pp-2016-0013_ref_063_w2aab3b7b2b1b6b1ab2b1c63Aa","doi-asserted-by":"crossref","unstructured":"63. Volm M, Efferth T. Prediction of Cancer Drug Resistance and Implications for Personalized Medicine. Front Oncol 2015;5:282.","DOI":"10.3389\/fonc.2015.00282"},{"key":"2025120909192062275_j_pp-2016-0013_ref_064_w2aab3b7b2b1b6b1ab2b1c64Aa","doi-asserted-by":"crossref","unstructured":"64. Quent VMC, Loessner D, Friis T, Reichert JC, Hutmacher DW. Discrepancies between metabolic activity and DNA content as tool to assess cell proliferation in cancer research. J Cell Mol Med 2010;14:1003\u201313.","DOI":"10.1111\/j.1582-4934.2010.01013.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_065_w2aab3b7b2b1b6b1ab2b1c65Aa","doi-asserted-by":"crossref","unstructured":"65. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005;11:127\u201352.","DOI":"10.1016\/S1387-2656(05)11004-7"},{"key":"2025120909192062275_j_pp-2016-0013_ref_066_w2aab3b7b2b1b6b1ab2b1c66Aa","doi-asserted-by":"crossref","unstructured":"66. Lopez-Barcons LA. Serially heterotransplanted human prostate tumors as an experimental model. J Cell Mol Med 2010;14:1385\u201395.","DOI":"10.1111\/j.1582-4934.2009.00957.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_067_w2aab3b7b2b1b6b1ab2b1c67Aa","doi-asserted-by":"crossref","unstructured":"67. Ng KW, Leong DTW, Hutmacher DW. The challenge to measure cell proliferation in two and three dimensions. Tissue Eng 2005;11:182\u201391.","DOI":"10.1089\/ten.2005.11.182"},{"key":"2025120909192062275_j_pp-2016-0013_ref_068_w2aab3b7b2b1b6b1ab2b1c68Aa","doi-asserted-by":"crossref","unstructured":"68. Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P. Comparison of alamar blue and MTT assays for high through-put screening. Toxicol in Vitro 2004;18:703\u201310.","DOI":"10.1016\/j.tiv.2004.03.012"},{"key":"2025120909192062275_j_pp-2016-0013_ref_069_w2aab3b7b2b1b6b1ab2b1c69Aa","doi-asserted-by":"crossref","unstructured":"69. O\u2018Brien J, Wilson I, Orton T, Pognan F. Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 2000;267:5421\u20136.","DOI":"10.1046\/j.1432-1327.2000.01606.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_070_w2aab3b7b2b1b6b1ab2b1c70Aa","doi-asserted-by":"crossref","unstructured":"70. Mironova EV, Evstratova AA, Antonov SM. A fluorescence vital assay for the recognition and quantification of excitotoxic cell death by necrosis and apoptosis using confocal microscopy on neurons in culture. J Neurosci Methods 2007;163:1\u20138.","DOI":"10.1016\/j.jneumeth.2007.02.010"},{"key":"2025120909192062275_j_pp-2016-0013_ref_071_w2aab3b7b2b1b6b1ab2b1c71Aa","doi-asserted-by":"crossref","unstructured":"71. Blaheta RA, Kronenberger B, Woitaschek D, Weber S, Scholz M, Schuldes H, et\u2009al. Development of an ultrasensitive in vitro assay to monitor growth of primary cell cultures with reduced mitotic activity. J Immunol Methods 1998;211:159\u201369.","DOI":"10.1016\/S0022-1759(97)00202-0"},{"key":"2025120909192062275_j_pp-2016-0013_ref_072_w2aab3b7b2b1b6b1ab2b1c72Aa","doi-asserted-by":"crossref","unstructured":"72. Otvos R, Skribek H, Kis LL, Gloghini A, Markasz L, Flaberg E, et\u2009al. Drug sensitivity patterns of HHV8 carrying body cavity lymphoma cell lines. BMC Cancer 2011;11:441.","DOI":"10.1186\/1471-2407-11-441"},{"key":"2025120909192062275_j_pp-2016-0013_ref_073_w2aab3b7b2b1b6b1ab2b1c73Aa","doi-asserted-by":"crossref","unstructured":"73. Skribek H, Otvos R, Flaberg E, Nagy N, Markasz L, Eksborg S, et\u2009al. Chronic lymphoid leukemia cells are highly sensitive to the combination of prednisolone and daunorubicin, but much less to doxorubicin or epirubicin. Exp Hematol 2010;38:1219\u201330.","DOI":"10.1016\/j.exphem.2010.09.001"},{"key":"2025120909192062275_j_pp-2016-0013_ref_074_w2aab3b7b2b1b6b1ab2b1c74Aa","doi-asserted-by":"crossref","unstructured":"74. Flaberg E, Sabelstrom P, Strandh C, Szekely L. Extended Field Laser Confocal Microscopy (EFLCM): combining automated Gigapixel image capture with in silico virtual microscopy. BMC Med Imaging 2008;8:13.","DOI":"10.1186\/1471-2342-8-13"},{"key":"2025120909192062275_j_pp-2016-0013_ref_075_w2aab3b7b2b1b6b1ab2b1c75Aa","doi-asserted-by":"crossref","unstructured":"75. Markasz L, Kis LL, Stuber G, Flaberg E, Otvos R, Eksborg S, et\u2009al. Hodgkin-lymphoma-derived cells show high sensitivity to dactinomycin and paclitaxel. Leukemia Lymphoma 2007;48:1835\u201345.","DOI":"10.1080\/10428190701559132"},{"key":"2025120909192062275_j_pp-2016-0013_ref_076_w2aab3b7b2b1b6b1ab2b1c76Aa","doi-asserted-by":"crossref","unstructured":"76. Szulkin A, Otvos R, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, et\u2009al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer 2014;14:709.","DOI":"10.1186\/1471-2407-14-709"},{"key":"2025120909192062275_j_pp-2016-0013_ref_077_w2aab3b7b2b1b6b1ab2b1c77Aa","doi-asserted-by":"crossref","unstructured":"77. Otvos R, Szulkin A, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, et\u2009al. Drug sensitivity profiling and molecular characteristics of cells from pleural effusions of patients with lung adenocarcinoma. Genes Cancer 2015;6:119\u201328.","DOI":"10.18632\/genesandcancer.56"},{"key":"2025120909192062275_j_pp-2016-0013_ref_078_w2aab3b7b2b1b6b1ab2b1c78Aa","doi-asserted-by":"crossref","unstructured":"78. Von Hoff DD. He\u2019s not going to talk about in vitro predictive assays again, is he?. J Natl Cancer Inst 1990;82:96\u2013101.","DOI":"10.1093\/jnci\/82.2.96"},{"key":"2025120909192062275_j_pp-2016-0013_ref_079_w2aab3b7b2b1b6b1ab2b1c79Aa","doi-asserted-by":"crossref","unstructured":"79. Kim HK, Moon H, Lee KS, Moon HS, Kim BS, Kim DJ. Clonogenic assay of gastric adenocarcinoma stem cells--clonogenic assay, stomach cancer. Korean J Intern Med 1987;2:163\u20139.","DOI":"10.3904\/kjim.1987.2.2.163"},{"key":"2025120909192062275_j_pp-2016-0013_ref_080_w2aab3b7b2b1b6b1ab2b1c80Aa","unstructured":"80. Ballet F, Petit J, Poupon R, Darnis F. Soft agar clonogenic assay for predicting chemosensitivity of human tumor cells from malignant effusions. Biomedicine 1981;35:177\u20138."},{"key":"2025120909192062275_j_pp-2016-0013_ref_081_w2aab3b7b2b1b6b1ab2b1c81Aa","doi-asserted-by":"crossref","unstructured":"81. Dittrich C, Dittrich E, Wrba F, Hudec M, Grunt T, Salzer H, et\u2009al. Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patients. Cancer Lett 1990;50:183\u20139.","DOI":"10.1016\/0304-3835(90)90263-W"},{"key":"2025120909192062275_j_pp-2016-0013_ref_082_w2aab3b7b2b1b6b1ab2b1c82Aa","doi-asserted-by":"crossref","unstructured":"82. Staquet M, Brown Jr BW, Rozencweig M, Van Muylder E, Dodion P, Sanders C. Validation of the clinical predictive values of the in vitro phase II clonogenic assay in cancer of the breast and ovary. Am J Clin Oncol 1987;10:485\u201390.","DOI":"10.1097\/00000421-198712000-00005"},{"key":"2025120909192062275_j_pp-2016-0013_ref_083_w2aab3b7b2b1b6b1ab2b1c83Aa","unstructured":"83. Sikic BIRM, Carter SK, editors. Bleomycin chemotherapy. New York: Academic Press, 1985."},{"key":"2025120909192062275_j_pp-2016-0013_ref_084_w2aab3b7b2b1b6b1ab2b1c84Aa","unstructured":"84. Diessner J, Bruttel V, Stein RG, Horn E, Hausler SF, Dietl J, et\u2009al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell Death Dis 2014;5:e1149."},{"key":"2025120909192062275_j_pp-2016-0013_ref_085_w2aab3b7b2b1b6b1ab2b1c85Aa","unstructured":"85. Miller BE, Miller FR, Heppner GH. Interactions between tumor subpopulations affecting their sensitivity to the antineoplastic agents cyclophosphamide and methotrexate. Cancer Res 1981;41:4378\u201381."},{"key":"2025120909192062275_j_pp-2016-0013_ref_086_w2aab3b7b2b1b6b1ab2b1c86Aa","doi-asserted-by":"crossref","unstructured":"86. Barrett KL, Willingham JM, Garvin AJ, Willingham MC. Advances in cytochemical methods for detection of apoptosis. J Histochem Cytochem 2001;49:821\u201332.","DOI":"10.1177\/002215540104900703"},{"key":"2025120909192062275_j_pp-2016-0013_ref_087_w2aab3b7b2b1b6b1ab2b1c87Aa","unstructured":"87. Szulkin A, Nilsonne G, Mundt F, Wasik AM, Souri P, Hjerpe A, et\u2009al. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy. PLoS One 2013;8:e65903."},{"key":"2025120909192062275_j_pp-2016-0013_ref_088_w2aab3b7b2b1b6b1ab2b1c88Aa","doi-asserted-by":"crossref","unstructured":"88. Dong HP, Kleinberg L, Davidson B, Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc 2008;3:955\u201364.","DOI":"10.1038\/nprot.2008.77"},{"key":"2025120909192062275_j_pp-2016-0013_ref_089_w2aab3b7b2b1b6b1ab2b1c89Aa","doi-asserted-by":"crossref","unstructured":"89. Dong HP, Holth A, Ruud MG, Emilsen E, Risberg B, Davidson B. Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays. Cytopathology 2011;22:365\u201372.","DOI":"10.1111\/j.1365-2303.2010.00811.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_090_w2aab3b7b2b1b6b1ab2b1c90Aa","doi-asserted-by":"crossref","unstructured":"90. Davidson B, Dong HP, Berner A, Risberg B. The diagnostic and research applications of flow cytometry in cytopathology. Diagn Cytopathol 2012;40:525\u201335.","DOI":"10.1002\/dc.22809"},{"key":"2025120909192062275_j_pp-2016-0013_ref_091_w2aab3b7b2b1b6b1ab2b1c91Aa","doi-asserted-by":"crossref","unstructured":"91. Bennett TA, Montesinos P, Moscardo F, Martinez-Cuadron D, Martinez J, Sierra J, et\u2009al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk 2014;14:305\u201318.","DOI":"10.1016\/j.clml.2013.11.006"},{"key":"2025120909192062275_j_pp-2016-0013_ref_092_w2aab3b7b2b1b6b1ab2b1c92Aa","doi-asserted-by":"crossref","unstructured":"92. Roscilli G, De Vitis C, Ferrara FF, Noto A, Cherubini E, Ricci A, et\u2009al. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J Transl Med 2016;14:61.","DOI":"10.1186\/s12967-016-0816-x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_093_w2aab3b7b2b1b6b1ab2b1c93Aa","doi-asserted-by":"crossref","unstructured":"93. Lee JY, Kim SY, Park C, Kim NK, Jang J, Park K, et\u2009al. Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget 2015;6:25619\u201330.","DOI":"10.18632\/oncotarget.4627"},{"key":"2025120909192062275_j_pp-2016-0013_ref_094_w2aab3b7b2b1b6b1ab2b1c94Aa","doi-asserted-by":"crossref","unstructured":"94. Akiyoshi T, Wada T, Nakamura Y. Clinical correlations with chemosensitivities measured in a simplified tritiated thymidine incorporation assay in patients with malignant effusion. Oncology 1990;47:418\u201321.","DOI":"10.1159\/000226861"},{"key":"2025120909192062275_j_pp-2016-0013_ref_095_w2aab3b7b2b1b6b1ab2b1c95Aa","doi-asserted-by":"crossref","unstructured":"95. Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et\u2009al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med 2014;6:237).","DOI":"10.1126\/scitranslmed.3008639"},{"key":"2025120909192062275_j_pp-2016-0013_ref_096_w2aab3b7b2b1b6b1ab2b1c96Aa","doi-asserted-by":"crossref","unstructured":"96. Mouriquand J, Mouriquand C, Petitpas E, Mermet MA. Long-term tissue cultures of human pleural effusions: a cytological follow-up. In Vitro 1978;14:591\u2013600.","DOI":"10.1007\/BF02617918"},{"key":"2025120909192062275_j_pp-2016-0013_ref_097_w2aab3b7b2b1b6b1ab2b1c97Aa","doi-asserted-by":"crossref","unstructured":"97. Sun X, Dobra K, Bjornstedt M, Hjerpe A. Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation 2000;66:181\u20138.","DOI":"10.1046\/j.1432-0436.2000.660404.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_098_w2aab3b7b2b1b6b1ab2b1c98Aa","doi-asserted-by":"crossref","unstructured":"98. Sun X, Wei L, Liden J, Hui G, Dahlman-Wright K, Hjerpe A, et\u2009al. Molecular characterization of tumor heterogeneity and malignant mesothelioma cell differentiation by gene profiling. J Pathol 2005;207:91\u2013101.","DOI":"10.1002\/path.1810"},{"key":"2025120909192062275_j_pp-2016-0013_ref_099_w2aab3b7b2b1b6b1ab2b1c99Aa","doi-asserted-by":"crossref","unstructured":"99. Dobra K, Andang M, Syrokou A, Karamanos NK, Hjerpe A. Differentiation of mesothelioma cells is influenced by the expression of proteoglycans. Exp Cell Res 2000;258:12\u201322.","DOI":"10.1006\/excr.2000.4915"},{"key":"2025120909192062275_j_pp-2016-0013_ref_100_w2aab3b7b2b1b6b1ab2b1d100Aa","doi-asserted-by":"crossref","unstructured":"100. Rundlof AK, Fernandes AP, Selenius M, Babic M, Shariatgorji M, Nilsonne G, et\u2009al. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation 2007;75:123\u201332.","DOI":"10.1111\/j.1432-0436.2006.00121.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_101_w2aab3b7b2b1b6b1ab2b1d101Aa","doi-asserted-by":"crossref","unstructured":"101. Sun X, Gulyas M, Hjerpe A, Dobra K. Proteasome inhibitor PSI induces apoptosis in human mesothelioma cells. Cancer Lett 2006;232:161\u20139.","DOI":"10.1016\/j.canlet.2005.02.022"},{"key":"2025120909192062275_j_pp-2016-0013_ref_102_w2aab3b7b2b1b6b1ab2b1d102Aa","doi-asserted-by":"crossref","unstructured":"102. Nilsonne G, Sun X, Nystrom C, Rundlof AK, Potamitou Fernandes A, Bjornstedt M, et\u2009al. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 2006;41:874\u201385.","DOI":"10.1016\/j.freeradbiomed.2006.04.031"},{"key":"2025120909192062275_j_pp-2016-0013_ref_103_w2aab3b7b2b1b6b1ab2b1d103Aa","doi-asserted-by":"crossref","unstructured":"103. Madeja Z, Sroka J, Nystrom C, Bjorkhem-Bergman L, Nordman T, Damdimopoulos A, et\u2009al. The role of thioredoxin reductase activity in selenium-induced cytotoxicity. Biochem Pharmacol 2005;69:1765\u201372.","DOI":"10.1016\/j.bcp.2005.02.023"},{"key":"2025120909192062275_j_pp-2016-0013_ref_104_w2aab3b7b2b1b6b1ab2b1d104Aa","doi-asserted-by":"crossref","unstructured":"104. Gandin V, Nystrom C, Rundlof AK, Jonsson-Videsater K, Schonlau F, Horkko J, et\u2009al. Effects of the antioxidant Pycnogenol on cellular redox systems in U1285 human lung carcinoma cells. Febs J 2009;276:532\u201340.","DOI":"10.1111\/j.1742-4658.2008.06800.x"},{"key":"2025120909192062275_j_pp-2016-0013_ref_105_w2aab3b7b2b1b6b1ab2b1d105Aa","doi-asserted-by":"crossref","unstructured":"105. Rudolf E, Rudolf K, Cervinka M. Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells. Cell Biol Toxicol 2008;24:123\u201341.","DOI":"10.1007\/s10565-007-9022-1"},{"key":"2025120909192062275_j_pp-2016-0013_ref_106_w2aab3b7b2b1b6b1ab2b1d106Aa","doi-asserted-by":"crossref","unstructured":"106. Husbeck B, Nonn L, Peehl DM, Knox SJ. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 2006;66:218\u201325.","DOI":"10.1002\/pros.20337"},{"key":"2025120909192062275_j_pp-2016-0013_ref_107_w2aab3b7b2b1b6b1ab2b1d107Aa","doi-asserted-by":"crossref","unstructured":"107. Bjorkhem-Bergman L, Jonsson K, Eriksson LC, Olsson JM, Lehmann S, Paul C, et\u2009al. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem Pharmacol 2002;63:1875\u201384.","DOI":"10.1016\/S0006-2952(02)00981-4"},{"key":"2025120909192062275_j_pp-2016-0013_ref_108_w2aab3b7b2b1b6b1ab2b1d108Aa","doi-asserted-by":"crossref","unstructured":"108. Jonsson-Videsater K, Bjorkhem-Bergman L, Hossain A, Soderberg A, Eriksson LC, Paul C, et\u2009al. Selenite-induced apoptosis in doxorubicin-resistant cells and effects on the thioredoxin system. Biochem Pharmacol 2004;67:513\u201322.","DOI":"10.1016\/j.bcp.2003.09.021"},{"key":"2025120909192062275_j_pp-2016-0013_ref_109_w2aab3b7b2b1b6b1ab2b1d109Aa","doi-asserted-by":"crossref","unstructured":"109. Nilsonne G, Olm E, Szulkin A, Mundt F, Stein A, Kocic B, et\u2009al. Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure. J Exp Clin Cancer Res 2009;28:92.","DOI":"10.1186\/1756-9966-28-92"},{"key":"2025120909192062275_j_pp-2016-0013_ref_110_w2aab3b7b2b1b6b1ab2b1d110Aa","doi-asserted-by":"crossref","unstructured":"110. Vilmar AC, Santoni-Rugiu E, Sorensen JB. Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial. Ann Oncol 2013;24:309\u201314.","DOI":"10.1093\/annonc\/mds335"},{"key":"2025120909192062275_j_pp-2016-0013_ref_111_w2aab3b7b2b1b6b1ab2b1d111Aa","doi-asserted-by":"crossref","unstructured":"111. Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. BMC Cancer 2014;14:304.","DOI":"10.1186\/1471-2407-14-304"},{"key":"2025120909192062275_j_pp-2016-0013_ref_112_w2aab3b7b2b1b6b1ab2b1d112Aa","unstructured":"112. D\u2018Arcangelo M, Todaro M, Salvini J, Benfante A, Colorito ML, D\u2018Incecco A, et\u2009al. Cancer stem cells sensitivity assay (STELLA) in patients with advanced lung and colorectal cancer: a feasibility study. PLoS One 2015;10:e0125037."},{"key":"2025120909192062275_j_pp-2016-0013_ref_113_w2aab3b7b2b1b6b1ab2b1d113Aa","doi-asserted-by":"crossref","unstructured":"113. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008;283:13021\u201330.","DOI":"10.1074\/jbc.M709698200"},{"key":"2025120909192062275_j_pp-2016-0013_ref_114_w2aab3b7b2b1b6b1ab2b1d114Aa","doi-asserted-by":"crossref","unstructured":"114. Wilson SM, Barbone D, Yang TM, Jablons DM, Bueno R, Sugarbaker DJ, et\u2009al. mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids. Am J Respir Cell Mol Biol 2008;39:576\u201383.","DOI":"10.1165\/rcmb.2007-0460OC"},{"key":"2025120909192062275_j_pp-2016-0013_ref_115_w2aab3b7b2b1b6b1ab2b1d115Aa","doi-asserted-by":"crossref","unstructured":"115. Barbone D, Follo C, Echeverry N, Gerbaudo VH, Klabatsa A, Bueno R, et\u2009al. Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models. PLoS One 2015;10:e0134825.","DOI":"10.1371\/journal.pone.0134825"},{"key":"2025120909192062275_j_pp-2016-0013_ref_116_w2aab3b7b2b1b6b1ab2b1d116Aa","doi-asserted-by":"crossref","unstructured":"116. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Hata K, et\u2009al. Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Sur 2007;133:303\u20138.","DOI":"10.1016\/j.jtcvs.2006.06.030"},{"key":"2025120909192062275_j_pp-2016-0013_ref_117_w2aab3b7b2b1b6b1ab2b1d117Aa","doi-asserted-by":"crossref","unstructured":"117. Isogai A, Nagaya M, Matsuoka H, Watanabe T, Tsukikawa S, Kubota S. A new chemosensitivity assay for ascites tumor cells using a thermoreversible gelation polymer as a culture medium and the observed clinical responses. Eur Surg Res 2007;39:41\u201350.","DOI":"10.1159\/000098439"},{"key":"2025120909192062275_j_pp-2016-0013_ref_118_w2aab3b7b2b1b6b1ab2b1d118Aa","unstructured":"118. Higashiyama M, Oda K, Okami J, Maeda J, Kodama K, Takami K, et\u2009al. In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application. Ann Thorac Cardiovasc Surg 2008;14:355\u201362."},{"key":"2025120909192062275_j_pp-2016-0013_ref_119_w2aab3b7b2b1b6b1ab2b1d119Aa","doi-asserted-by":"crossref","unstructured":"119. Kawamura M, Gika M, Abiko T, Inoue Y, Oyama T, Izumi Y, et\u2009al. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemoth Pharmacol 2007;59:507\u201313.","DOI":"10.1007\/s00280-006-0292-8"},{"key":"2025120909192062275_j_pp-2016-0013_ref_120_w2aab3b7b2b1b6b1ab2b1d120Aa","unstructured":"120. Higashiyama M, Okami J, Maeda J, Tokunaga T, Fujiwara A, Kodama K, et\u2009al. Differences in chemosensitivity between primary and paired metastatic lung cancer tissues: In vitro analysis based on the collagen gel droplet embedded culture drug test (CD-DST). J Thorac Dis 2012;4:30\u201347."},{"key":"2025120909192062275_j_pp-2016-0013_ref_121_w2aab3b7b2b1b6b1ab2b1d121Aa","doi-asserted-by":"crossref","unstructured":"121. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H, Noguchi S. Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 2002;98:450\u20135.","DOI":"10.1002\/ijc.10208"},{"key":"2025120909192062275_j_pp-2016-0013_ref_122_w2aab3b7b2b1b6b1ab2b1d122Aa","doi-asserted-by":"crossref","unstructured":"122. Takebayashi K, Mekata E, Sonoda H, Shimizu T, Endo Y, Tani T. Clinical potential of the anticancer drug sensitivity test for patients with synchronous stage IV colorectal cancer. Cancer Chemoth Pharmacol 2013;72:217\u201322.","DOI":"10.1007\/s00280-013-2189-7"},{"key":"2025120909192062275_j_pp-2016-0013_ref_123_w2aab3b7b2b1b6b1ab2b1d123Aa","unstructured":"123. Kawaguchi M, Banno K, Susumu N, Yanokura M, Kuwabara Y, Hirao N, et\u2009al. Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: Case reports. Anticancer Res 2005;25:3547\u201351."},{"key":"2025120909192062275_j_pp-2016-0013_ref_124_w2aab3b7b2b1b6b1ab2b1d124Aa","doi-asserted-by":"crossref","unstructured":"124. Yabushita H, Ohnishi M, Komiyama M, Mori T, Noguchi M, Kishida T, et\u2009al. Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer. Oncol Rep 2004;12:307\u201311.","DOI":"10.3892\/or.12.2.307"},{"key":"2025120909192062275_j_pp-2016-0013_ref_125_w2aab3b7b2b1b6b1ab2b1d125Aa","doi-asserted-by":"crossref","unstructured":"125. Alifrangis C, Janssen JQ, Badhai J, Iorio F, Schunselaar L, Kolluri K, et\u2009al. High throughput therapeutic screening of malignant pleural mesothelioma (MPM) to identify correlation of sensitivity to FGFR inhibitors with BAP1 inactivation. J Clin Oncol 2015;33.","DOI":"10.1200\/jco.2015.33.15_suppl.7563"},{"key":"2025120909192062275_j_pp-2016-0013_ref_126_w2aab3b7b2b1b6b1ab2b1d126Aa","unstructured":"126. Roe OD, Szulkin A, Anderssen E, Flatberg A, Sandeck H, Amundsen T, et\u2009al. Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma. PLoS One 2012;7:e40521."},{"key":"2025120909192062275_j_pp-2016-0013_ref_127_w2aab3b7b2b1b6b1ab2b1d127Aa","doi-asserted-by":"crossref","unstructured":"127. Takeuchi S, Seike M, Noro R, Soeno C, Sugano T, Zou F, et\u2009al. Significance of osteopontin in the sensitivity of malignant pleural mesothelioma to pemetrexed. Int J Oncol 2014;44:1886\u201394.","DOI":"10.3892\/ijo.2014.2370"},{"key":"2025120909192062275_j_pp-2016-0013_ref_128_w2aab3b7b2b1b6b1ab2b1d128Aa","doi-asserted-by":"crossref","unstructured":"128. Costello JC, Heiser LM, Georgii E, Gonen M, Menden MP, Wang NJ, et\u2009al. A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 2014;32:1202\u201312.","DOI":"10.1038\/nbt.2877"},{"key":"2025120909192062275_j_pp-2016-0013_ref_129_w2aab3b7b2b1b6b1ab2b1d129Aa","doi-asserted-by":"crossref","unstructured":"129. Khan SA, Faisal A, Mpindi JP, Parkkinen JA, Kalliokoski T, Poso A, et\u2009al. Comprehensive data-driven analysis of the impact of chemoinformatic structure on the genome-wide biological response profiles of cancer cells to 1159 drugs. BMC Bioinf 2012;13:112.","DOI":"10.1186\/1471-2105-13-112"},{"key":"2025120909192062275_j_pp-2016-0013_ref_130_w2aab3b7b2b1b6b1ab2b1d130Aa","doi-asserted-by":"crossref","unstructured":"130. Szulkin A, Otvos R, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, et\u2009al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer 2014;14:709.","DOI":"10.1186\/1471-2407-14-709"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/1\/3\/article-p119.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0013\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0013\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T09:51:05Z","timestamp":1765273865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2016-0013\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":130,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,9,15]]},"published-print":{"date-parts":[[2019,4,24]]}},"alternative-id":["10.1515\/pp-2016-0013"],"URL":"https:\/\/doi.org\/10.1515\/pp-2016-0013","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}